SGM-101

Phase 2Small molecule

LLeiden University Medical Center

SGM-101 is one of 19 small molecule programs targeting Brain Metastases. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain MetastasesRecruiting

Brain MetastasesPhase 2

Recruiting

Competition

Competitive Landscape

21 competitors in Brain Metastases

#DrugCompanyPhaseTrials

Tagrisso

AstraZeneca

Phase 2

7 2

Keytruda

Merck & Co.

Phase 2

3 3

Namenda

AbbVie

Phase 2

2 4

Perjeta

Roche

Phase 2

1 5

Tukysa

Pfizer

Phase 2

1 6

Trodelvy

Gilead

Phase 2

1 7

Almonertinib

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3

3 8

Krazati

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

2 9

Decadron

AAspen Global Incorporated

Phase 2

2 10

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pulmonary Nodules1 trial

Intraoperative Imaging of Pulmonary Nodules by SGM-101

Completed·SSunil Singhal·Phase 1·NCT04315467·10 enrolled

Brain Metastases1 trial

SGM-101 in Colorectal Brain Metastases.

Recruiting·LLeiden University Medical Center·Phase 2·NCT04755920·10 enrolled

Colorectal Cancer1 trial

Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

Recruiting·SSurgimab·Phase 3·NCT03659448·300 enrolled

Recurrent Rectal Cancer1 trial

SGM-101 in Locally Advanced and Recurrent Rectal Cancer

Unknown status·LLeiden University Medical Center·Phase 2/3·NCT04642924·203 enrolled

Lung Metastases1 trial

SGM-101 in Colorectal Lung Metastases

Unknown status·LLeiden University Medical Center·Phase 2·NCT04737213·10 enrolled

2 more indications

Cancer1 trial

Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas

Completed·SSurgimab·Phase 1/2·NCT02973672·75 enrolled

Adenocarcinoma1 trial

SGM-101 Tumor Targeted Fluorescence Endoscopy in Rectal Polyps With Suspected T1 Adenocarcinoma or High Grade Dysplasia

Unknown status·LLeiden University Medical Center·Phase 2·NCT06280690·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for SGM-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SGM-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SGM-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Leiden University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLeiden University Medical Center

SGM-101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pulmonary Nodules1 trial

Brain Metastases1 trial

Colorectal Cancer1 trial

Recurrent Rectal Cancer1 trial

Lung Metastases1 trial

Cancer1 trial

Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News